MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
Categorie
Financial
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
April 9, 2024
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale Lyon, France, April 5 2024…
April 5, 2024
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview The DSMB, based on Phase 3 trial ARES preliminary…
March 28, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
March 7, 2024
MaaT Pharma Releases its 2024 Financial Calendar Lyon, France, March 7, 2024 –6:00pm CET – MaaT Pharma (EURONEXT: MAAT –…
March 7, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Lyon, France, February…
February 8, 2024
MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France, January 22nd, 2024 – 6:00…
January 22, 2024
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
January 8, 2024
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
December 5, 2023
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.